Comparison of Cyfra 21–1 and Squamous Cell Carcinoma Antigen in Detecting Nasopharyngeal Carcinoma

CYFRA 21–1 is a newly developed tumor marker that is especially useful for detecting squamous cell carcinoma (SCC) of the lung. Squamous cell carcinoma antigen is a proven tumor marker that is especially useful for detecting SCC of the cervix. Our aim in this study was to compare the clinical value of CYFRA 21–1 and SCC antigen in the detection of nasopharyngeal carcinoma (NPC). Serum levels of CYFRA 21–1 and SCC antigen were measured in 80 untreated NPC patients and 77 healthy controls. The cutoff values of CYFRA 21–1 and SCC antigen, determined at the 95th percentile of the 77 healthy controls, were 2.48 ng/mL and 1.49 ng/mL, respectively. The results revealed that the mean serum value of only CYFRA 21–1 was significantly higher in the 80 NPC patients than in the 77 healthy controls, and the detection sensitivity of CYFRA 21–1 for NPC was significantly higher than that of SCC antigen. In conclusion, our results suggest that CYFRA 21–1 is a better tumor marker than SCC antigen for detection of NPC.

[1]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[2]  J. Nikliński,et al.  Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. , 1995, The European respiratory journal.

[3]  W. Riesen,et al.  [CYFRA 21-1: initial experiences in bronchus carcinoma and other tumors]. , 1994, Schweizerische medizinische Wochenschrift.

[4]  K. Eguchi,et al.  Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients. , 1994, Japanese journal of clinical oncology.

[5]  J. Nikliński,et al.  Evaluation of CYFRA 21–1 as a new marker for non‐small cell lung cancer , 1994, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[6]  N. Dahlmann,et al.  Tumor markers in the diagnosis and follow‐up of head and neck cancer: Role of CEA, CA 19‐9, SCC, TK, and dttpase , 1993, Head & neck.

[7]  J. Johnson,et al.  The lack of utility of a tumor marker panel in head and neck carcinoma. Squamous cell carcinoma antigen, carcinoembryonic antigen, lipid-associated sialic acid, and CA-125. , 1992, Archives of otolaryngology--head & neck surgery.

[8]  R. Cantrell,et al.  Effective head and neck tumor markers. The continuing quest. , 1991, Archives of otolaryngology--head & neck surgery.

[9]  Jonas T. Johnson,et al.  SCC‐RIA in the diagnosis of squamous cell carcinoma of the head and neck , 1989, The Laryngoscope.

[10]  S. Wagenaar,et al.  Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. , 1988, Cancer research.

[11]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[12]  H. Kato,et al.  Radioimmunoassay for tumor-antigen of human cervical squamous cell carcinoma. , 1977, Cellular and molecular biology, including cyto-enzymology.

[13]  T. H. van der Kwast,et al.  Immunoelectron microscopic studies on cytokeratins in human basal cell carcinoma. , 1989, Anticancer research.

[14]  R. Moll,et al.  Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. , 1984, The American journal of pathology.